BiotechTube
CLS Therapeutics

CLS Therapeutics

New York, United States· Est.
clstherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CLS Therapeutics is translating the emerging biology of circulating nucleic acids into transformative gene therapies for cancer. Founded by scientists and biotech entrepreneurs, the company is advancing its lead program, CLS-014, a novel AAV vector encoding a hyperactive DNase I enzyme, to clean pathogenic cfDNA from patients' blood. With a team of experts in cfDNA research, gene therapy, and oncology, CLS is focused on treating gastrointestinal cancers and has engaged in strategic collaborations to advance its platform.

OncologyGastrointestinal Cancer

Technology Platform

AAV vector-based gene therapy platform designed to deliver engineered enzymes (e.g., hyperactive DNase I) into the bloodstream to degrade circulating cell-free DNA (cfDNA), a pro-tumorigenic factor in cancer.

Opportunities

The platform technology targeting cfDNA has potential application beyond pancreatic cancer to multiple solid tumors, representing a significant expansion opportunity.
Successful proof-of-concept could also open doors for diagnostic-therapeutic combinations or partnerships with larger oncology-focused pharmaceutical companies.

Risk Factors

The core scientific premise of therapeutically targeting cfDNA is novel and unproven in clinical settings, carrying high biological risk.
As an AAV-based gene therapy, the program faces development challenges related to immunogenicity, manufacturing, and delivery.
The company is at a preclinical stage and will require substantial capital to advance, introducing significant financial and dilution risk.

Competitive Landscape

CLS Therapeutics is a pioneer in the direct therapeutic degradation of cfDNA, with few, if any, direct competitors. It competes indirectly with the entire spectrum of oncology therapeutics. Its main differentiation is its first-in-class mechanism targeting a systemic driver of cancer progression rather than the tumor cell itself, which could offer a complementary approach to existing treatments.

More companies in Cell & Gene Therapy →More companies in United States →